Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future immunotherapies in multiple sclerosis.

Gregg Blevins1, Roland Martin

  • 1Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Building 10, Room 5B16, 10 Center Drive, Bethesda, MD 20892-1400, USA.

Seminars in Neurology
|August 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-resolution fluid-suppressed diffusion tractography of the fornix across the healthy lifespan and deviations in multiple sclerosis.

Imaging neuroscience (Cambridge, Mass.)·2026
Same author

Therapeutic immune tolerance for central nervous system autoimmune diseases - Prospects, challenges and pitfalls.

Seminars in immunology·2026
Same author

Distinct Clinico-pathogenic Subgroups in Pediatric Lyme Neuroborreliosis.

Open forum infectious diseases·2026
Same author

Anoctamin-2-specific T cells link Epstein-Barr virus to multiple sclerosis.

Cell·2026
Same author

EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation.

Cell·2026
Same author

Protocol for the characterization of autoproliferating B and T cells from persons with multiple sclerosis.

STAR protocols·2025
Same journal

Isolated Cranial Tremors: A Reappraisal.

Seminars in neurology·2026
Same journal

Dystonia and Tremor.

Seminars in neurology·2026
Same journal

Pendular nystagmus and oculopalatal tremor.

Seminars in neurology·2026
Same journal

Sanjay Pandey, MBBS, MD, DNB, DM, FIAN, and Aasef Shaikh, MD, PhD.

Seminars in neurology·2026
Same journal

Tremor.

Seminars in neurology·2026
Same journal

Carotid Disease.

Seminars in neurology·2026
See all related articles

Future multiple sclerosis (MS) immunotherapies will leverage deeper disease understanding for targeted treatments. Personalized combination therapies, addressing individual disease states, promise greater efficacy than single agents for heterogeneous MS patient groups.

Area of Science:

  • Neuroimmunology
  • Autoimmune disease therapeutics
  • Multiple Sclerosis (MS) research

Background:

  • Multiple sclerosis (MS) immunotherapy is evolving with increased disease insight.
  • Current MS therapies show modest efficacy due to disease heterogeneity.
  • Understanding MS complexity is crucial for developing effective treatments.

Purpose of the Study:

  • To discuss the development of future immunotherapies for multiple sclerosis.
  • To classify novel therapeutic approaches into three main categories.
  • To highlight the importance of personalized medicine in MS treatment.

Main Methods:

  • Classification of future immunotherapies into: antigen-specific, targeted pathogenic steps, and broad immunomodulatory agents.
  • Analysis of the impact of disease complexity and heterogeneity on therapeutic success.

Related Experiment Videos

  • Review of current limitations of single-agent therapies in heterogeneous MS populations.

    • Main Results:

    • Future immunotherapies will be guided by a deeper understanding of MS.
    • Novel therapeutic strategies include antigen-specific, targeted, and broad immunomodulatory approaches.
    • Disease heterogeneity necessitates tailored treatment strategies.

    Conclusions:

    • Future MS therapy will likely involve combination treatments.
    • Personalized approaches targeting individual disease states and stages are essential.
    • Overcoming modest efficacy requires addressing MS heterogeneity with tailored immunotherapies.